Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunshine Biopharma's revenue for the
three
months ended in Jun. 2026 was $9.26 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $35.35 Mil.
Sunshine Biopharma's Revenue per Share for the
three
months ended in Jun. 2026 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00.
Warning Sign:
Sunshine Biopharma Inc revenue per share has been in decline over the past 3 years.
During the past 13 years, Sunshine Biopharma's highest 3-Year average Revenue per Share Growth Rate was -72.80% per year. The lowest was -72.80% per year. And the median was -72.80% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Sunshine Biopharma Revenue Related Terms
Sunshine Biopharma Revenue Historical Data
* Premium members only.
The historical data trend for Sunshine Biopharma's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Revenue distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $35.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma (SBFMW) has a Revenue of $35.35 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Sunshine Biopharma and its competitors.
Is Sunshine Biopharma's Revenue too high?
Sunshine Biopharma's current Revenue is $35.35 Mil. Overall, Sunshine Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's Revenue compare to BUDZ and CVSI?
Sunshine Biopharma's Revenue of $35.35 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Sunshine Biopharma and its competitors. Sunshine Biopharma's current Revenue is $35.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Sunshine Biopharma (SBFMW) has a current Revenue of $35.35 Mil. The current Revenue is $35.35 Mil. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Sunshine Biopharma (SBFMW), the current Revenue is $35.35 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score
Get the complete analysis for SBFMW
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBFMW has been successfully added to your 
